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Abstract: Background
Genetic studies have strongly linked autophagy to Crohn's disease (CD) and
stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this
study was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on
autophagy and investigate molecular mechanisms of action and functional outcomes in
relation to this cellular process.
Methods
Autophagy marker LC3 was evaluated by confocal fluorescence microscopy and flow
cytometry. Drug mechanism of action was investigated by PCR Array with changes in
signaling pathways examined by immunoblot and RT-qPCR. Clearance of adherent-
invasive Escherichia coli (AIEC) and levels of pro-inflammatory cytokine tumour
necrosis factor alpha (TNFα) were evaluated by gentamicin protection assays and RT-
qPCR respectively. LC3 was analysed in peripheral blood mononuclear cells (PBMC)
from paediatric patients by flow cytometry.
Results
Azathioprine induces autophagy via mechanisms involving modulation of mechanistic
target of rapamycin (mTORC1) signaling and stimulation of the unfolded protein
response (UPR) sensor PERK. Induction of autophagy with azathioprine correlated
with the enhanced clearance of AIEC and dampened AIEC-induced increases in TNFα.
Azathioprine induced significant increase in autophagosome bound LC3-II in PBMC
populations ex vivo, supporting in vitro findings. In patients, the CD-associated
ATG16L1 T300A single-nucleotide polymorphism did not attenuate azathioprine
induction of autophagy.
Conclusions
Modulation of autophagy via mTORC1 and the UPR may contribute to the therapeutic
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
efficacy of azathioprine in IBD.
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Summary 26 
 27 
The aim of this study was to evaluate the effect of current inflammatory bowel disease drugs 28 
on autophagy and investigate molecular mechanisms of action and functional outcomes in 29 
relation to this cellular process. 30 
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Abstract  32 
Background: Genetic studies have strongly linked autophagy to Crohn's disease (CD) and 33 
stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this study 34 
was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on autophagy 35 
and investigate molecular mechanisms of action and functional outcomes in relation to this 36 
cellular process.  37 
Methods: Autophagy marker LC3 was evaluated by confocal fluorescence microscopy and 38 
flow cytometry. Drug mechanism of action was investigated by PCR Array with changes in 39 
signaling pathways examined by immunoblot and RT-qPCR. Clearance of adherent-invasive 40 
Escherichia coli (AIEC) and levels of pro-inflammatory cytokine tumour necrosis factor alpha 41 
(TNFα) were evaluated by gentamicin protection assays and RT-qPCR respectively. LC3 was 42 
analysed in peripheral blood mononuclear cells (PBMC) from pediatric patients by flow 43 
cytometry. 44 
Results: Azathioprine induces autophagy via mechanisms involving modulation of 45 
mechanistic target of rapamycin (mTORC1) signaling and stimulation of the unfolded protein 46 
response (UPR) sensor PERK. Induction of autophagy with azathioprine correlated with the 47 
enhanced clearance of AIEC and dampened AIEC-induced increases in TNFα. Azathioprine 48 
induced significant increase in autophagosome bound LC3-II in PBMC populations ex vivo, 49 
supporting in vitro findings. In patients, the CD-associated ATG16L1 T300A single-nucleotide 50 
polymorphism did not attenuate azathioprine induction of autophagy.  51 
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Conclusions: Modulation of autophagy via mTORC1 and the UPR may contribute to the 52 
therapeutic efficacy of azathioprine in IBD.  53 
Keywords:  Azathioprine, autophagy, mTORC1, unfolded protein response, Adherent-invasive 54 
E.coli. 55 
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Introduction 57 
  58 
The inflammatory bowel diseases (IBD), Crohn’s disease (CD), ulcerative colitis (UC) and IBD-59 
unclassified (IBDU), are characterized by chronic inflammation of the gastrointestinal (GI) 60 
tract and have a prevalence of up to 400 per 100,000 people in the United Kingdom 1. The 61 
pathogenesis of IBD is multifactorial in nature, with genetic predisposition, breakdown of the 62 
intestinal epithelial barrier, and concomitant interaction with environmental triggers in the 63 
lumen contributing to disease2. A dysregulated immune response to intestinal microflora has 64 
been heavily implicated, and examination of the disease-associated microbiome has 65 
identified several potentially causative agents 3. Most notably Escherichia coli (E.coli) strains 66 
with an adherent and invasive phenotype (AIEC) have been consistently isolated by 67 
independent investigators from CD patients with ileal disease 4.  68 
Genome-wide association studies (GWAS) have identified 240 IBD susceptibility loci to date5 69 
and have confirmed association with previously recognized susceptibility genes including 70 
Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2). Amongst genes 71 
identified are several linked to autophagy including autophagy-related protein (ATG)16L1, 72 
Immunity-related GTPase family M protein (IRGM) and leucine rich repeat kinase 2 (LRRK2) 6. 73 
Autophagy is an intracellular homeostatic process that involves the formation and maturation 74 
of double membrane vesicles, known as autophagosomes, which engulf cargo that is 75 
degraded upon fusion with lysosomes 7. Autophagy can be an important survival mechanism 76 
that is induced in response to a myriad of stresses. Autophagy plays an essential role in the 77 
innate and adaptive immune responses and the timely resolution of inflammation 8, and loss 78 
of immune regulation is a key event leading to the chronic inflammation observed in CD 9. 79 
Notably, impaired autophagy responses have been observed in a range of cell types derived 80 
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from CD patients including the specialized intestinal epithelial cells (IECs) Paneth cells and 81 
goblet cells, and leukocytes, such as macrophages and dendritic cells (DC) 10.  82 
Evidence suggests that inducing autophagy may have therapeutic benefit for the treatment 83 
of IBD 9. Mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cell 84 
growth and a potent inhibitor of autophagy 10, therefore inhibition of mTORC1 with 85 
rapamycin or its analogues, sirolimus and everolimus, strongly induces autophagy. In 86 
previously reported case studies sirolimus improved symptoms and intestinal healing in a 87 
patient with severe refractory CD 11 and everolimus controlled symptoms for 18 months in a 88 
patient with refractory UC 12. In a study of refractory pediatric IBD, sirolimus induced clinical 89 
remission in 45% of UC patients and 100% of CD patients 13.  90 
Drugs currently approved for clinical use for IBD, including corticosteroids, 91 
immunomodulators, aminosalicylates (5-ASAs) and biologics, target the immune system to 92 
reduce inflammation and induce remission, however response to treatment often diminishes 93 
over time, with 10–35% of CD patients requiring surgery within a year of diagnosis and up to 94 
61% by 10 years 14. A National Health Service review estimated IBD treatment costs of £720 95 
million ($940m) per year in the United Kingdom alone 1, with roughly a quarter of these costs 96 
directly attributed to drug treatments 15. The Crohn’s and Colitis Foundation has recently 97 
highlighted the need for research into optimizing existing medical therapies 16, with patient 98 
stratification of key importance in this context 13. In order to optimize therapies, a more 99 
comprehensive understanding of drug mechanisms of action is required.  100 
We aimed to evaluate current IBD drugs in the context of autophagy and show that the 101 
immunomodulator azathioprine induces autophagy via mechanisms involving modulation of 102 
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mTORC1 and stimulation of the unfolded protein response (UPR) sensor PERK. Our results 103 
suggest that in addition to well-characterized effects on DNA/RNA synthesis and T-104 
lymphocytes 17,18, modulation of autophagy and the UPR may contribute to the therapeutic 105 
efficacy of azathioprine.  106 
  107 
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Materials and Methods 108 
Cell culture, transfection, plasmids and reagents 109 
HEK293 cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Gibco, 110 
ThermoFisher Scientific, Paisley, UK) supplemented with 10% foetal bovine serum (FBS) 111 
(Invitrogen, ThermoFisher Scientific) and penicillin streptomycin (Gibco). The monocytic THP-112 
1 cell line was grown in RPMI 1640 (Sigma-Aldrich, Irvine, UK), supplemented with 10% FBS, 113 
penicillin streptomycin and 200mM L-glutamine (Gibco). For differentiation to macrophages, 114 
THP-1 cells were incubated in RPMI growth media supplemented with 10ng/ml phorbol 115 
myristate acetate (PMA) (Sigma-Aldrich, Dorset, UK) for 48 hr, then rested for 24 hr in fresh 116 
RPMI growth media prior to experiments.  117 
For transfection of HEK293 cells, a Nucleofector Kit V (Lonza Ltd, Manchester, UK) was used 118 
according to the manufacturer’s instructions. The GFP-LC3 19, GFP-RFP-LC3 20 and x-light EGFP 119 
21 plasmids have been described previously. All reagents used are detailed in supplementary 120 
(Table S1). For nutrient deprivation, cells were incubated with Earle’s Balanced Salt Solution 121 
(EBSS) (Gibco).  122 
Immunoblotting 123 
Cells were lysed in ice-cold extraction buffer (50mM Tris [pH 7.6], 150mM NaCl, 5mM EDTA, 124 
0.5% NP-40, 5mM NaF, 1mM sodium vanadate, 1 × Pierce Protease Inhibitor Cocktail [Thermo 125 
Scientific]) for 30 min followed by centrifugation. Protein lysates were resolved by denaturing 126 
electrophoresis on acrylamide/bisacrylamide gels and electro-transferred to Immobilon-FL 127 
PVDF membrane (Merck Millpore EMD, Watford, UK). Membranes were incubated with 128 
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primary antibodies overnight at 4°C, and after washing, were incubated with a secondary 129 
antibody for 1hr at room temperature (RT). Antibody details are provided in (Table S2). 130 
Proteins were visualized by incubation with an ECL western blotting analysis system (GE 131 
Healthcare) and imaged using a G: BOX system (Syngene, Cambridge, UK). Relative intensity 132 
of bands were measured using Image J software 22 (National Institutes of Health, Bethesda, 133 
MD, USA). 134 
Confocal fluorescence microscopy 135 
Cells were seeded on 21-mm borosilicate glass cover slips, 8 chamber polystyrene vessel 136 
CultureSlides (Falcon, Fisher Scientific, Loughborough, UK) or 35mm imaging dishes (Ibidi, 137 
Thistle Scientific, Uddingston, UK). Images were captured using Carl Zeiss LSM880 confocal 138 
microscope (Jena, Germany) and images were analysed using Image J software 18  (National 139 
Institutes of Health). 140 
For fixed cell imaging: Cells were fixed with 4% paraformaldehyde (PFA) for 15 min, 141 
permeabilized with PBS/0.2% Triton X-100 (Sigma Aldrich) and blocked with PBS containing 142 
10% goat’s serum (Gibco) and 2.5% Human TruStain FcX (BioLegend, San Diego, USA). Primary 143 
antibodies (Table S2) were incubated overnight at 4°C and conjugated secondary antibodies 144 
for 1hr at RT. Where appropriate, cells were counterstained with 4′,6′-diamidino-2-145 
phenylindole (DAPI) or mounted with Vectashield mounting medium for fluorescence with 146 
DAPI (Vector Laboratories, Peterborough, UK).  147 
For live cell imaging: Cells were grown in 35mm imaging dishes (Ibidi) and maintained at 37oC 148 
and 5% CO2 in live-cell imaging chamber attached to Carl Zeiss LSM880 confocal microscope. 149 
Images were captured every 2 minutes at x40 magnification over a 12hr time period. 150 
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For autophagy assays in HEK293 GFP-LC3 stable cells: The basal threshold number of GFP-LC3 151 
puncta per cell was established as 5, and cells exhibiting ≥5 puncta were regarded as having 152 
enhanced autophagy activity.   153 
For tandem fluorescent-tagged GFP-RFP-LC3 assays: Cells were transiently transfected with 154 
the GFP-RFP-LC3 plasmid and following designated treatments, the fluorescent autophagy 155 
markers GFP-RFP-LC3 or RFP-LC3 were observed using a confocal microscope and the number 156 
of (RFP+GFP+) and (RFP+GFP-) puncta per cell determined. 157 
Flow cytometry 158 
Peripheral blood mononuclear cells (PBMC) were seeded in 96-well U-bottom plates and cell 159 
lines were seeded in 12-well plates. After treatments, cells were gently detached using 0.05% 160 
trypsin or Cell Dissociation Solution Non-enzymatic (Sigma Aldrich) at 37°C for 10 min. Cells 161 
were acquired using the BD Biosciences (Oxford, UK) Celesta flow cytometer or the 162 
FACSCalibur (BD) and data analysis performed using BD FACsDiva Software or FlowJo 163 
software. 164 
Autophagy assay: For HEK293 GFP-LC3, cells were collected then washed in 0.05% w/v 165 
saponin (Sigma), diluted in PBS to remove the unbound cytosolic LC3 23, which does not alter 166 
expression of membrane antigens 24, prior to acquisition. For PBMC, cells were collected and 167 
blocked with 2.5% Human TruStain FcX in PBS for 20 min, then incubated with PBMC surface 168 
markers or IgG isotypes diluted in Brilliant Stain Buffer (BD Horizon) for 25 min, both at RT. 169 
Cells were then washed in 0.05% w/v saponin, diluted in PBS to remove the unbound cytosolic 170 
LC3, and fixed with 1% PFA for 20 min at 4oC. Cells were washed again with 10% goat serum 171 
in 0.05% saponin before overnight incubation with primary LC3 antibody or Rb IgG Isotype 172 
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control (Invitrogen) in 1% goat serum in 0.05% saponin at 4oC. Secondary antibody in 1% goat 173 
serum in 0.05% saponin was incubated for 30 min at 4oC prior to washing and acquisition.  174 
Annexin-V/PI assay. Cells were stained using the FITC Annexin V Apoptosis Detection Kit I (BD 175 
Pharmingen) according to manufacturer’s instructions.  176 
RT-qPCR 177 
Cells were scraped into RNAzol RT (Sigma-Aldrich) and total RNA extracted according to 178 
manufacturer’s instructions. Total RNA was quantified using a NanoDrop 2000 179 
Spectrophotometer (Thermo Scientific) and integrity was assessed using an Agilent 2100 180 
Bioanalyzer (Agilent Technologies, Stockport, UK) with RNA Nano Chips and Agilent RNA 6000 181 
Nano Reagents (Agilent Technologies). mRNA was converted to cDNA using nanoScript 2, 182 
Reverse Transcription Premix (PrimerDesign Ltd, Chandler´s Ford, UK) according to 183 
manufacturer’s instructions. For qPCR analysis of gene expression PrecisionPLUS Mastermix 184 
with SYBR green and ROX with inert blue dye (PrimerDesign) was used according to 185 
manufacturer’s instructions with RT-PCR Grade Water (Invitrogen) and the StepOnePlus Real-186 
time PCR System (Applied Biosystems, ThermoFisher). Primers are detailed in supplementary 187 
(Table S3). A geNorm kit (PrimerDesign) was used for the selection of appropriate reference 188 
genes (RPL13A [Ribosomal Protein L13a] and Actin) with the qbase+ software 25. 2-ddCT was 189 
used for relative quantification of gene expression 26. The RT² Profiler PCR Array of Human 190 
Autophagy genes (Qiagen, Crawley, UK) was performed according to manufacturer 191 
instructions. 192 
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Bacterial infection assays 193 
For growth curves: LB was inoculated with E. coli strain CUICD541-10 27 isolated from the 194 
ileum of a patient with CD (a kind gift from Prof Kenny Simpson, Cornell University, USA), from 195 
an overnight culture to an optical density of 0.05 at 600nM. Cultures were treated 196 
appropriately, incubated at 37oC with 200rpm shaking, and optical density was measured at 197 
600nM every 30 min.    198 
For intracellular survival: Cells were infected with CUICD541-10 E. coli at a multiplicity of 199 
infection (MOI) of 10 for 3hr, incubated for 1hr in 100μg/ml gentamicin (Gibco) to kill 200 
extracellular bacteria, then maintained for a further 24hr in 20μg/ml gentamicin, with 201 
addition of appropriate treatments for the final 6hr. For colony forming unit (CFU) 202 
enumeration, cells were lysed for 10 min using 1% Triton X100 in PBS. Lysates were serially 203 
diluted and plated on LB agar plates for overnight incubation at 37°C.  204 
For immunofluorescence: CUICD541-10 E. coli transformed with an x-light mCherry plasmid 205 
were used and 30 min prior to immunostaining cells were incubated with 0.1mM isopropyl β‐206 
D‐1‐thiogalactopyranosid (IPTG) (Sigma) to promote bacterial fluorescence. IPTG and 5µM 207 
Cell Tracker Green BODIPY (Invitrogen) were added for the duration of the live-cell imaging 208 
of infected cells.  209 
Patients 210 
Patient recruitment and sample collection was performed at the Royal Hospital for Sick 211 
Children in Edinburgh, and processing and analysis was performed at Edinburgh Napier 212 
University.  213 
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Inclusion criteria were: (1) aged 6-18 years on date of colonoscopy; (2) already confirmed CD, 214 
UC or IBDU 28 or undergoing first upper and lower GI endoscopy due to gastrointestinal 215 
symptoms suggestive of possible bowel inflammation (e.g. abdominal pain, peri-rectal (PR) 216 
bleeding, weight loss). Non-IBD patients were defined as those with both microscopically and 217 
macroscopically normal colonoscopy. Patients were excluded if they had previously 218 
undergone colonoscopy for anything other than known IBD, were diagnosed with anything 219 
other than IBD following a full investigative cycle, or who could not provide written consent. 220 
Whole blood samples (maximum 15ml), and saliva samples were collected from patients: 20 221 
IBD cases and 9 non-IBD controls (Table S4). PBMC were isolated from whole blood using 222 
Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and cultured in RPMI 223 
growth media. Saliva samples were collected using Oragene DNA kits (DNA Genotek, Ontario, 224 
Canada). 225 
Genotyping  226 
Saliva samples were sent to the Wellcome Trust Clinical Research Facility in Edinburgh for 227 
analysis. Once recruitment was completed, DNA was extracted using Isohelix kit and Taqman 228 
genotyping for each sample was performed for the following SNPs: ATG16L1 T300A 229 
(rs2241880), NOD2 L1007f/s (p.Leu1007fsX1008) (rs2066847), NOD2 R702W (rs2066844) and 230 
NOD2 G908R (rs2066845). 231 
Statistical analysis 232 
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Results are reported as the mean ± SEM assuming normally distributed variables with 233 
statistical analysis conducted by using one-way or two-way ANOVA, or paired t-test as 234 
appropriate, with GraphPad Prism version 7.0 (GraphPad Software, CA, USA). 235 
Ethics 236 
All samples were collected with local institutional and NHS ethical approvals (reference 237 
16/WW/0210).  Eligible patients were approached at least 48hr prior to colonoscopy and 238 
following consent were recruited to the study.  239 
Data availability 240 
The datasets generated during and/or analysed during the current study are available from 241 
the corresponding author on reasonable request. 242 
  243 
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Results 244 
Azathioprine induces autophagosome accumulation 245 
To evaluate the modulation of autophagy by IBD drugs we used HEK293 cells, a well-246 
characterized cell line used in autophagy research 29 that were engineered to stably express 247 
the autophagy marker LC3 fused to green fluorescent protein (GFP-LC3) 30. GFP-LC3 puncta 248 
accumulation was measured by live-cell imaging (Figure 1A). Significant increases in GFP-LC3 249 
puncta number were observed after treatment with the immunomodulator azathioprine 250 
(Figure 1A, panel iv and ix) and the biologic infliximab (Figure 1A, panel v and ix) with an 251 
optimal time-point of 6 hr for both drugs (Figure 1A, panel x and xi). Significant increases in 252 
GFP-LC3 puncta were also observed with EBSS to induce nutrient deprivation, a strong 253 
activator of the autophagy pathway (Figure 1A, panel iii and ix). In contrast, the 254 
immunomodulator methotrexate (Figure 1A, panel vi, ix and xii), the corticosteroid 255 
methylprednisolone (Figure 1A, panel vii, ix and xiii) and the aminosalicylate sulfasalazine 256 
(Figure 1A, panel viii, ix and xiv) had no significant effects on GFP-LC3 puncta accumulation.  257 
Azathioprine activates the autophagy pathway 258 
Autophagosomes can accumulate due to activation or inhibition of the autophagy pathway. 259 
To distinguish between these processes, we first employed flow cytometric analysis. To 260 
facilitate measurement of autophagy activation by flow cytometry, HEK293 GFP-LC3 cells 261 
were washed with the glycoside saponin to permeabilize cell plasma membranes prior to 262 
analysis. Plasma membrane permeabilization releases inactive cytosolic LC3, with only the 263 
active lipidated form of LC3-II, which is tightly associated with autophagosome membranes, 264 
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being retained 23 (Supplementary Figure 1). Additionally, Bafilomycin A1 (BafA1), an inhibitor 265 
of autophagosome-lysosome fusion30, was used to augment LC3-II accumulation. Under these 266 
conditions azathioprine clearly enhanced the accumulation of autophagosome-bound GFP-267 
LC3-II (Figure 2A, panel ii and quantified in iv). In contrast, infliximab had only minor additional 268 
effect on GFP-LC3-II accumulation (Figure 2A, panel iii and iv).  269 
To further validate that azathioprine-mediated activation of the autophagy pathway, we 270 
employed a tandem RFP-GFP-LC3 plasmid 31. This RFP-GFP-LC3 plasmid utilises the pH 271 
difference between the acidic autolysosome (formed by fusion of an autophagosome and 272 
lysosome) and the neutral autophagosome, with the pH sensitivity differences exhibited by 273 
GFP (labile at acidic pH) and RFP (stable at acidic pH). Thus, this plasmid can be used to 274 
monitor progression from the autophagosome (RFP+GFP+) to the autolysosome (RFP+GFP-). 275 
HEK293 cells were transfected with RFP-GFP-LC3 plasmid and treated with BafA1, EBSS or 276 
azathioprine. As expected, all three treatments caused autophagosomes to accumulate 277 
(Figure 2B, panel xvi). Inhibition of autophagosome-lysosome fusion with BafA1 resulted in 278 
the accumulation of  (RFP+GFP+) puncta, which appear as yellow in the merged image (Figure 279 
2B, panel x, xiii and quantified in xvii), while activation of the pathway with EBSS resulted in 280 
an accumulation of (RFP+GFP-) puncta indicating that complete progression through the 281 
pathway was taking place (Figure 2B, panel xi, xiv and xvii). Azathioprine treatment resulted 282 
in an accumulation of (RFP+GFP-) puncta relative to untreated control (Figure 2B, panel xii, xv 283 
and xvii) indicating that azathioprine activates the autophagy pathway. 284 
Azathioprine induces autophagosome accumulation in macrophages 285 
independent of apoptosis 286 
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As with other biological processes, autophagy is cell-type specific and it is therefore essential 287 
to determine how azathioprine modulates the autophagy pathway in cell types of direct 288 
relevance to IBD. For this purpose, macrophages derived from THP-1 cells were treated with 289 
azathioprine and endogenous LC3 puncta accumulation measured by fixed-cell confocal 290 
fluorescence microscopy. In line with our previous results (Figure 1A), azathioprine treatment 291 
significantly increased the number of LC3 puncta in THP-1 derived macrophages (Figure 3A, 292 
panel iv and v). Autophagy and apoptosis are intimately linked 32, therefore it was also 293 
important to determine the effect of azathioprine on apoptosis in these cells. Analysis of 294 
Annexin V/PI staining by flow cytometry revealed that azathioprine had no effect on cell 295 
viability at either 6 hr or 24 hr treatment (Figure 3B, panel ii, iv, and v). Together, these results 296 
demonstrate that azathioprine induces autophagosome accumulation in THP-1 derived 297 
macrophages independent of apoptosis. 298 
Azathioprine stimulates the UPR  299 
To gain insight into azathioprine mechanism of action, we used the Human Autophagy RT² 300 
Profiler PCR Array. Gene expression was compared in THP-1 derived macrophages either left 301 
untreated or treated with azathioprine (Figure S3).  Among the genes significantly up-302 
regulated by azathioprine was the UPR-regulating kinase EIF2AK3 (also known as PERK). As 303 
endoplasmic reticulum (ER)-stress/UPR genes are strongly associated with IBD this was 304 
investigated further 33. A time-course RT-qPCR experiment identified 6 hr as the optimum 305 
time-point for up regulation of PERK, which occurred in a dose-dependent manner (Figure 4, 306 
panel i and ii). The expression of genes downstream from PERK (ATF4, and CHOP; Figure 4, 307 
panel iii and iv), and the ER stress chaperon protein disulphide isomerase (PDI) (Figure 4, panel 308 
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vi) were also up regulated after 6 hr of azathioprine treatment in a dose dependent manner. 309 
In contrast, expression of the ER stress chaperone protein binding immunoglobulin 310 
protein/78-kDa glucose-regulated protein (BiP/Grp78) was not affected by azathioprine 311 
treatment after 6 hr (Figure 4, panel vii) however a minor increase was observed after 24 hr. 312 
These results indicate that azathioprine stimulates the UPR.   313 
Azathioprine modulates mTORC1 signaling 314 
mTORC1 is a major regulatory hub balancing cell growth and protein translation with control 315 
of autophagy 34. When active, mTORC1 is a potent inhibitor of autophagy. Therefore, levels 316 
of phosphorylated ribosomal protein S6 (p-rpS6), a surrogate marker of mTORC1 activity, 317 
were evaluated in THP-1 derived macrophages treated with increasing concentrations of 318 
azathioprine. Azathioprine treatment caused a dramatic decrease in p-rpS6 in a dose 319 
dependent manner (Figure 5A, lanes 3-6 and quantified in ii). These results suggest that 320 
azathioprine treatment inhibits mTORC1 activity. 321 
Azathioprine modulates mTORC1 signaling independent of PERK 322 
PERK has been shown to inhibit mTORC1 in response to ER stress as part of a mechanism to 323 
induce autophagy 34–36. To test whether modulation of mTORC1 observed in response to 324 
azathioprine is dependent on PERK, THP-1 derived macrophages were treated in the absence 325 
or presence of a pharmacologic inhibitor of PERK. Azathioprine again caused a decrease in p-326 
rpS6, and the PERK inhibitor did not significantly alter this effect (Figure 5B, panel i, compare 327 
lanes 3 and 8, and quantified in ii). To confirm PERK inhibitor activity, phosphorylation of 328 
eIF2a, a well-characterized substrate of PERK, was assessed (Figure 5B, lanes 6-10 and 329 
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quantified in iii). These results suggest that modulation of mTORC1 signaling by azathioprine 330 
occurs independent of PERK. 331 
Azathioprine-induced autophagy is modulated by PERK 332 
To determine whether PERK is required for azathioprine-induced autophagy, THP-1 derived 333 
macrophages were treated with azathioprine or EBSS in the absence or presence of PERK 334 
inhibitor. In the presence of PERK inhibitor, azathioprine-induced autophagy was specifically 335 
attenuated (Figure 5C, compare panel ii and v, and quantified in vii) compared to EBSS-336 
induced autophagy (Figure 5C, compare panel iii and vi, and quantified in vii). These results 337 
indicate that PERK is an important factor regulating azathioprine-induced autophagy.  338 
Azathioprine enhances clearance of intracellular AIEC 339 
Evidence suggests that AIEC play a putative role in CD 37. Therefore, we evaluated the survival 340 
of the CD mucosa-associated AIEC strain CUICD541-10 27 in THP-1 derived macrophages. 341 
Initially, it was determined that azathioprine had no direct effect on bacterial growth (Figure 342 
S3). Azathioprine treatment did however cause a significant decrease in bacterial CFU in AIEC 343 
infected cells (Figure 6A). Furthermore, immunofluorescence analysis showed a decrease in 344 
the percentage of cells infected with bacteria (Figure 6B and C, compare panels iii and iv and 345 
quantified in v), which correlated with an increased accumulation of LC3 puncta (Figure 6C 346 
panel v) indicating that autophagy was being induced.  347 
Infection of cells with AIEC elicits a strong inflammatory response; therefore, RT-qPCR was 348 
used to assess expression of the pro-inflammatory cytokine TNFα in THP-1 derived 349 
macrophages infected with AIEC. Expression was significantly up regulated by AIEC infection 350 
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and this was reduced when cells were treated with azathioprine (Figure 6D, panel i). 351 
Azathioprine also reduced the expression of TNFα in cells treated with bacterial 352 
lipopolysaccharide (LPS) (Figure 6D, panel ii) suggesting that azathioprine may affect TNFα 353 
expression independent of decreased intracellular bacteria. These results demonstrate that 354 
azathioprine enhances the clearance of intracellular AIEC and dampens the elevated cytokine 355 
levels observed in response to infection. 356 
Azathioprine activates autophagy in PBMC and monocytes from 357 
pediatric patients 358 
Non-IBD, CD and UC patients were genotyped for the CD-associated NOD2 (R702W, G908R, 359 
L1007fs) and ATG16L1 T300A SNPs (Table 1). PBMC from the patient groups were then 360 
assessed for autophagy activity by flow cytometry. No significant differences in basal 361 
autophagy activity were observed, and azathioprine treatment resulted in an accumulation 362 
of autophagosome-bound LC3-II in PBMC from all patient groups (Figure 7A, panel i).  Analysis 363 
of basal autophagy activity in untreated monocytes revealed no difference across the patient 364 
groups and azathioprine treatment again enhanced the accumulation of autophagosome-365 
bound LC3-II (Figure 7A, panel ii). Similar results were observed in monocyte subsets, in 366 
addition to T cells, B cells and NK cells (Figure S4). Interestingly, activation of autophagy by 367 
azathioprine was not attenuated in PBMC heterozygous or homozygous for the ATG16L1 368 
T300A SNP (Figure 7A, panel iii). The low frequency of NOD2 SNPs present in the cohort 369 
precluded analysis of effect on azathioprine-induced autophagy. Taken together, these 370 
results demonstrate that azathioprine activates autophagy in primary cells ex vivo, supporting 371 
our in vitro findings. 372 
373 
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Discussion  374 
 375 
The strong association of CD with autophagy genes has led to a substantial amount research 376 
demonstrating several key functions for autophagy including regulation of the innate and 377 
adaptive immune responses, regulation of the intestinal microbiome and resolution of ER-378 
stress 9,10. Impaired autophagy responses have been observed in a range of cell types derived 379 
from CD patients 10, and there is mounting evidence that inducing autophagy can have 380 
therapeutic benefits for the treatment of IBD in both pediatric and adult patients, with several 381 
recent studies investigating the utility of mTORC1 inhibitors 12,13,38. Despite these advances in 382 
understanding, there is still little known about how drugs currently approved for clinical use 383 
in IBD affect autophagy function.  384 
To evaluate current IBD drugs in the context of autophagy we initially screened for the 385 
accumulation of autophagosomes using live cell imaging and identified azathioprine and 386 
infliximab as potential modulators of autophagy. However, further investigation using flow 387 
cytometry to measure the active, lipidated form of LC3-II revealed that only azathioprine 388 
activated the autophagy pathway. Furthermore, results with the GFP-RFP-LC3 plasmid 389 
demonstrate that autophagic flux is enhanced in the presence of azathioprine.  390 
Thiopurines are a class of immunosuppressant drugs that includes azathioprine, 391 
mercaptopurine (6-MP), and thioguanine (6-TG). It is well-established that thiopurines can 392 
inhibit DNA/RNA synthesis and deactivate pro-inflammatory T-lymphocytes 17,18, however, 393 
their mechanism of action is not fully understood. Interestingly, several previous studies have 394 
also found that thiopurines can activate autophagy primarily via DNA mismatched repair 395 
processes in response to DNA damage 9. To date, only one study has shown autophagy 396 
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induction mediated by azathioprine, in colorectal carcinoma cells 39. The authors suggest that 397 
increased autophagy associated with thiopurine exposure is a survival mechanism to 398 
compensate for a primary effect on apoptosis and mitochondrial damage. Mechanistically, 399 
we show an alternative autophagy-associated process whereby azathioprine increased the 400 
expression of several UPR genes including PERK, ATF4 and CHOP as well as expression of the 401 
ER-stress chaperone protein PDI. Importantly, we demonstrate that azathioprine induces 402 
autophagy independent of apoptosis. 403 
The ER-stress/UPR pathways play an essential role in the maintenance of intestinal 404 
homeostasis and genetic studies have identified several ER-stress/UPR genes associated with 405 
IBD 33. Significantly, ER-stress levels are increased in ileal and colonic biopsies from CD 406 
patients 40–43. The UPR acts to maintain ER-homeostasis, and cells that naturally secrete large 407 
amounts of protein, such as Paneth cells strongly linked to ileal CD are more susceptible to 408 
ER-stress and therefore rely heavily on the UPR 44 .  409 
The UPR and autophagy are intimately linked processes 45, to relieve ER-stress the UPR can 410 
induce autophagy to degrade misfolded proteins and protein aggregates 46–50. Importantly, 411 
the major risk factors for CD, NOD2 and ATG16L1, functionally intersect with ER-stress and 412 
the UPR 51 52, and ER stress is a significant risk when autophagy or the UPR is not functional. 413 
The convergence between autophagy and UPR pathways provides new opportunity for the 414 
treatment of IBD and the modulation of the UPR in combination with autophagy is a promising 415 
therapeutic strategy. In support of this idea, several recent studies have demonstrated 416 
beneficial effects of enhancing UPR function for intestinal homeostasis 53–55.  417 
We also show that azathioprine modulates mTORC1 signaling. A growing body of work 418 
suggests that the UPR is regulated by diverse stimuli independently of ER-stress 56 and 419 
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stressors such as nutrient deprivation and hypoxia have been shown to activate UPR signaling 420 
and inhibit mTORC1 57. UPR activation can occur both upstream and downstream of mTORC1 421 
57, and mTORC1 inhibitors, including rapamycin, are reported to induce PERK and eIF2α  422 
activation 58. Our finding that PERK inhibition did not affect the mTORC1 response to 423 
azathioprine suggests that mTORC1 may be acting upstream or in parallel to PERK. 424 
Significantly, azathioprine-induced autophagy was reduced in the presence of PERK inhibitor, 425 
supporting others findings that PERK regulates LC3B and ATG5 expression 59. Our results 426 
suggest that azathioprine is acting through a pathway that involves both mTORC1 and PERK, 427 
and may have synergistic outcomes; mTORC1 inhibition and PERK-eIF2α stimulation may 428 
work together to inhibit global protein translation, while mTORC1 inhibition together with 429 
increased expression of autophagy genes by PERK 60,61, may result in a general increase in 430 
autophagic activity.  431 
AIEC are prevalent in ileal mucosa of CD patients 62 and are able to survive and replicate within 432 
macrophages, resulting in sustained inflammatory responses 63 and granuloma formation 64. 433 
Using a CD mucosa-associated strain of AIEC we show that azathioprine enhances the 434 
clearance of intracellular bacteria from THP-1 derived macrophages independent of direct 435 
effects on bacterial growth. Importantly, AIEC clearance correlated with increased autophagy 436 
and reduced pro-inflammatory cytokine gene expression.  These combined effects of 437 
azathioprine may make it a preferred therapeutic option for subsets of patients with 438 
confirmed AIEC infection.  439 
Finally, we carried out an observational study of a clinical cohort of children. PBMC from non-440 
IBD patients or patients with the diagnosis of IBD were analysed to determine basal 441 
autophagy levels and response to azathioprine treatment ex vivo. Our flow cytometry results 442 
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revealed that basal autophagy levels and azathioprine-induced autophagy were similar in all 443 
patient groups.  Similar results were also observed when we analysed subsets of monocytes, 444 
T cells, B cells and NK cells.  Importantly, it has been shown that autophagy is required for the 445 
differentiation of monocytes to macrophages 65, and for the induction of macrophages which 446 
display immunosuppressive and wound healing properties 66. Our results suggest that 447 
enhancing autophagy with azathioprine may promote the induction of macrophages with an 448 
anti-inflammatory phenotype irrespective of diagnosis.   449 
Greater understanding of the genetic factors that underlie CD pathogenesis are leading to 450 
improvements in treatment, and genotyping for key SNPs in genes involved in both the 451 
autophagy and ER-stress/UPR pathways may help to predict patient response to drugs. For 452 
example, recent studies have identified an association between ATG16L1 T300A SNP and an 453 
enhanced therapeutic effect of thiopurines 67 and anti-TNF-α therapy 68. Interestingly, the 454 
immunoregulatory effects of these drugs were associated with autophagy stimulation 66,67,69. 455 
For instance, cytoskeletal defects that reduced mobility in autophagy-deficient DC harbouring 456 
the ATG16L1 T300A SNP were reversed by thiopurine inhibition of Ras-related C3 botulinum 457 
toxin substrate 1 (RAC1) 67. Significantly, analysis of ATG16L1 genotype in our pediatric cohort 458 
revealed that the autophagy response to azathioprine was not attenuated in PBMC from 459 
patients carrying the CD-associated T300A SNP. The ATG16L1 T300A risk variant confers 460 
greater risk for CD in pediatric patients than in adult patients 70,71 , therefore it will be 461 
interesting to compare results in PBMC from an adult cohort. Collectively, our studies suggest 462 
that patients harbouring the ATG16L1 risk variant may benefit from thiopurines via 463 
mechanisms involving RAC1 inhibition and the induction of autophagy. 464 
Conclusion  465 
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Breakdown of the ER-stress/UPR and autophagy pathways has been strongly linked to 466 
pathogenesis of IBD. Together, our results suggest that stimulation of autophagy and the UPR 467 
may contribute to the therapeutic efficacy of azathioprine. Additional studies are now 468 
required to further elucidate how thiopurines modulate these converging pathways; results 469 
of these studies may pave the way for development of the next generation of drugs aimed at 470 
modulation of the UPR in combination with autophagy. 471 
Autophagy is a cell type specific process, therefore it is essential to assess whether 472 
thiopurines modulate autophagy and the UPR in other cell types of direct relevance to IBD, 473 
such as Paneth cells strongly linked to ileal CD. Specifically, studies conducted in cells from 474 
patients with known CD-associated mutations in the genes regulating the ER-stress/UPR and 475 
autophagy pathways will help to identify patients that are most likely to respond. 476 
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AIEC  Adherent Invasive E. coli   677 
ATF6  Activating transcription factor 6 678 
ATG16L1 Autophagy-related protein 16-1 679 
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ER  Endoplasmic Reticulum 690 
FBS  Foetal bovine serum  691 
GI  Gastrointestinal tract  692 
GWAS  Genome-wide association studies 693 
IBD  Inflammatory Bowel Disease 694 
IBDU  IBD-unclassified  695 
IPTG  isopropyl β‐D‐1‐thiogalactopyranosid 696 
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 714 
Table 1. Pediatric patient genotype 715 
CD Crohn’s disease, UC Ulcerative colitis, IBDU IBD unclassified. ATG16L1 T300A genotype: 716 
rs2241880. *NOD2 genotype SNPs: L1007fs (rs2241880), G908R (rs2066845) and R702W 717 
(rs2066844). 718 
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 Non-IBD CD UC IBDU 
Cohort (n=29) 9 12 7 1 
Genotype ATG16L1 T300A (n=26) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
1 
3 
3 
 
2 
6 
4 
 
1 
3 
3 
 
N/A 
N/A 
N/A 
Genotype NOD2 L1007fs (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
8 
0 
0 
 
12 
0 
0 
 
7 
0 
0 
 
N/A 
N/A 
N/A 
Genotype NOD2 G908R (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
8 
0 
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11 
0 
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N/A 
Genotype NOD2 R702W  (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
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N/A 
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Figure Legends  720 
Figure 1: Modulation of autophagy by current IBD drugs  721 
HEK293 GFP-LC3 cells were untreated (i) or treated with DMSO (ii), EBSS (iii), 120μM 722 
Azathioprine (iv and x), 100μg/ml Infliximab (v and xi), 120μM Methotrexate (vi and xii), 723 
100μM methylprednisolone (vii and xiii) or 150μM sulfasalazine (viii and xiv) and assessed by 724 
live-cell confocal microscopy up to 12hr. 50 cells counted from 3 fields of view and percentage 725 
cells with >5 GFP-LC3 puncta quantified (+/- SEM) for all time-points (x-xiv) with 6hr time-726 
point highlighted **p <0.01; ****p < 0.0001 (ix). 727 
Figure 2: Azathioprine activates the autophagy pathway 728 
A) HEK293 GFP-LC3 cells were treated for 6hr with 160nM BafA1 only or BafA1 plus EBSS (i), 729 
BafA1 plus 120μM azathioprine (ii) or BafA1 plus 100μg/ml Infliximab (iii). Geometric mean 730 
of GFP-LC3-II intensity was assessed by flow cytometry. Fold-change in GFP-LC3-II geometric 731 
mean from BafA1 only was quantified (+/-SEM) (iv).  732 
B) HEK293 cells were transfected with GFP-RFP-LC3 plasmid and left untreated (i, v, ix) or 733 
treated with 160nM BafA1 (ii, vi, x), EBSS (iii, vii, xi), or 120µM azathioprine (iv, viii, xii) for 6hr, 734 
and imaged by confocal microscopy. Percentage of transfected cells exhibiting >10 LC3 puncta 735 
was quantified (+/-SEM) (n=5) (xiii) *p <0.05. Number of (RFP+GFP+) and (RFP+GFP-) LC3 736 
puncta were quantified (+/-SEM) (n=5) (xiv) **p <0.01, ***p <0.001. 737 
Figure 3: Azathioprine induces autophagosome accumulation independent of apoptosis 738 
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 A) THP-1-derived macrophages were untreated (i), or treated with DMSO (ii), EBSS (iii), or 739 
120µM azathioprine (iv) for 6hr. Cells were then immunostained for endogenous LC3 and 740 
imaged by confocal microscopy. 30 cells were counted from 3 fields of view and percentage 741 
cells with >5 GFP-LC3 puncta quantified (+/- SEM) *p <0.05; **p < 0.01 (v).  742 
B) THP-1-derived macrophages were left untreated (i, v) or treated with DMSO (ii, vi), 120μM 743 
azathioprine (iii, vii) or 30µM camptothecin (iv, viii) for 6hr (i-iv) and 24hr (v-vii). Cells were 744 
stained with Annexin-V/PI and analysed by flow cytometry. Mean percentage population in 745 
each quadrant was quantified (+/- SEM) **p value <0.01, ***p value <0.001, ****p value 746 
<0.0001 (ix) compared to untreated for corresponding time-point and quadrant. 747 
Figure 4: Azathioprine stimulates the UPR 748 
THP-1-derived macrophages were left untreated, or treated with DMSO, 60µM or 120µM 749 
azathioprine, or EBSS for 2, 4, 6, 16 and 24hr. Expression of PERK was determined by RT-qPCR 750 
and is displayed in Log10 scale (i). 6hr time-point, including treatment with 0.5μg/ml Brefeldin 751 
A quantification (+/- SEM) is shown for PERK (ii), ATF4 (iii), CHOP (iv), PDI (vi) and BiP (vii). 752 
Using 2-ddct : *p <0.05, **p <0.01, ****p <0.0001.  753 
Figure 5: Azathioprine modulates autophagy via mechanisms involving mTORC1 and PERK.  754 
A) THP-1-derived macrophages were left untreated or treated with DMSO, azathioprine (60-755 
120μM), EBSS or the mTORC1 inhibitor rapamycin (100nM) for 6hr. Protein lysates were 756 
immunoblotted for rpS6, phosphorylated rpS6 (p-rpS6 (S235/236)) and actin (i). rpS6/p-rpS6 757 
density normalized to actin was quantified as a percentage of untreated (ii). Representative 758 
blot from n=3. 759 
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B) THP-1-derived macrophages were left untreated, or treated with DMSO, 120µM 760 
azathioprine, EBSS, or 0.5μg/ml Brefeldin A for 6hr in the absence or presence of PERK 761 
inhibitor. Protein lysates were immunoblotted for rpS6, phosphorylated rpS6 (p-rpS6 762 
(S235/236)), phosphorylated eIF2α (p-eIF2α (S51) and tubulin (i). rpS6/p-rpS6 density (ii) and 763 
p-eIF2α density (iii) normalized to tubulin was quantified. Representative blot from n=3. 764 
C) THP-1-derived macrophages were left untreated, or treated with 120µM azathioprine, or 765 
EBSS for 6 hr in the absence (i-iii) and presence (iv-vi) of PERK inhibitor and immunostained 766 
for LC3. 100 cells were counted per treatment and percentage cells with >5 GFP-LC3 puncta 767 
quantified (+/- SEM) *p <0.05 (vii). 768 
Figure 6: Azathioprine enhances clearance of intracellular AIEC and dampens the 769 
inflammatory response.  770 
A) THP-1-derived macrophages were infected with AIEC and gentamicin protection assay 771 
performed in the absence or presence of DMSO or 120µM azathioprine. CFU/ml of cell lysates 772 
were enumerated, and fold-change mean CFU/ml from untreated was calculated (+/- SEM), 773 
**p <0.01.  774 
B and C) THP-1-derived macrophages were infected with AIEC-mCherry and gentamicin 775 
protection assay performed in the absence or presence of DMSO or 120µM azathioprine. 776 
Fluorescent AIEC were enumerated and percentage cells with intracellular bacteria quantified 777 
(+/- SEM), *p <0.05, **p <0.01, ***p <0.001. 778 
D) THP-1-derived macrophages were infected with AIEC (i) or treated with 200ng/ml LPS (ii) 779 
and left untreated or treated with DMSO or 120µM azathioprine for 6hr. Expression of TNF-α 780 
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was normalized to untreated and mean fold-change expression quantified from n=3 (+/- SEM) 781 
(i-ii). Using 2-ddct : *p <0.05. 782 
Figure 7: Azathioprine activates autophagy in PBMC and monocytes from pediatric patients.  783 
PBMC isolated from non-IBD control and IBD patients were left untreated or treated with 784 
120μM azathioprine for 6hr. PBMC were stained with surface markers for classification into 785 
populations and for endogenous LC3-II. Geometric mean of LC3-II intensity was quantified by 786 
flow cytometry and mean of LC3-II geometric mean (+/-SEM) is shown for total PBMC (I, iii) 787 
and total monocytes (ii) for each non-IBD and IBD patient group (i-ii) and each ATG16L1 788 
genotype (iii). One-way ANOVA with Tukey’s multiple comparison was used to compare LC3-789 
II geometric mean between patient groups in untreated cells. Within each patient group 790 
paired, two tailed t test was used to compare LC3-II geometric mean of untreated and 791 
azathioprine-treated cells.  *p < 0.05, **p <0.01. 792 
Table S1: Concentration and manufacturer details of reagents used for cell treatments. 793 
Working concentrations were diluted in appropriate growth media.  794 
Table S2: Antibody details  795 
WB western blot, IF immunofluorescent staining, F flow cytometry, IHC 796 
immunohistochemistry. All primary and secondary antibodies were prepared in 1% FBS or 797 
goat serum. 798 
Table S3: qPCR Primer Details 799 
FW forward and RV reverse primer sequences. 800 
Table S4: Pediatric patient demographics  801 
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CD Crohn’s disease, UC Ulcerative colitis, IBDU IBD unclassified. SD Standard deviation. *Non-802 
IBD diagnosis included normal (4 patients), mild constipation (1 patient), Irritable Bowel 803 
Syndrome (IBS) (3 patients) and threadworms (1 patient). aParis Classification for CD: L1 ileal, 804 
L2 colonic, L3 ileocolonic, L4a upper disease proximal to ligament of Treitz; B1 non-stricturing 805 
and non-penetrating, B2 stricturing, B3 penetrating, p perianal disease modifier 72. bParis 806 
Classification for UC: E1 ulcerative proctitis, E2 left-sided UC (distal to splenic flexure), E3 807 
extensive (hepatic flexure distally), E4 pancolitis (proximal to hepatic flexure); S0 never 808 
severe, S1 ever severe as defined by Pediatric Ulcerative Colitis Activity Index (PUCAI) 72. 5-809 
ASA 5-aminosalisylates. 810 
Figure S1: GFP-LC3 Flow Cytometry in HEK293 GFP-LC3 cells.  811 
Schematic diagram showing cell permeabilization with 0.05% saponin to remove cytosolic 812 
GFP-LC3 to allow flow cytometery analysis 23 (i). HEK293 GFP-LC3 cells were either untreated 813 
or treated with 160nM bafilomycin for 6 hours. Cells were washed without (ii) or with (iii) cell 814 
permeabilization with 0.05% saponin to remove cytosolic GFP-LC3 before fixation. Geometric 815 
mean of GFP-LC3 fluorescent intensity of cells was quantified by flow cytometry and analysed 816 
using FlowJo software (ii-iii). 817 
Figure S2: Differentially Expressed Genes from RT2 Profiler™ PCR Array for Human 818 
Autophagy Genes when treated with Azathioprine  819 
THP-1-derived macrophages were untreated or treated with 120µM azathioprine for 6 hours. 820 
mRNA was extracted and converted to cDNA for RT-qPCR analysis using the RT² Profiler™ PCR 821 
Array for Human Autophagy genes according to manufacturer instructions. The calibrating 822 
sample was untreated cells and relative expression for azathioprine treatment is displayed as 823 
fold-change, with upregulated genes calculated as 2-ddCT and downregulated genes as 2ddCT. 824 
Differentially expressed genes are shown, with 1.5-fold change in expression considered as 825 
the threshold for differential expression.  826 
Figure S3: Effect of azathioprine on growth of AIEC, clearance of intracellular AIEC and pro-827 
inflammatory cytokine responses  828 
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LB broth was inoculated from an overnight culture of AIEC to an optical density of 0.05 at 829 
600nm. The cultures were untreated, or treated with DMSO, or 120μM of azathioprine and 830 
incubated at 37oC with shaking at 200RPM. Optical density at 600nm was measured every 0.5 831 
hours and plotted in logarithmic scale to show growth phases.    832 
Figure S4: Azathioprine activates autophagy in monocyte subsets, T cells, B cells and NK 833 
cells from pediatric patients.  834 
PBMC isolated from non-IBD control and IBD patients were left untreated or treated with 835 
120μM azathioprine for 6h. PBMC were stained with surface markers for classification into 836 
populations and for endogenous LC3-II. Geometric mean of LC3-II intensity was quantified by 837 
flow cytometry and mean of LC3-II geometric mean (+/-SEM) is shown for classical monocytes 838 
(i), intermediate monocytes (ii), non-classical monocytes (iii), T cells (iv), B cells (v) and NK 839 
cells (vi) for each non-IBD and IBD patient group. One-way ANOVA with Tukey’s multiple 840 
comparison was used to compare LC3-II geometric mean between patient groups in 841 
untreated cells. Within each patient group paired, two tailed t test was used to compare LC3-842 
II geometric mean of untreated and azathioprine-treated cells.  *p < 0.05, **p <0.01. 843 
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Summary 26 
 27 
The aim of this study was to evaluate the effect of current inflammatory bowel disease drugs 28 
on autophagy and investigate molecular mechanisms of action and functional outcomes in 29 
relation to this cellular process. 30 
  31 
 3 
Abstract  32 
Background: Genetic studies have strongly linked autophagy to Crohn's disease (CD) and 33 
stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this study 34 
was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on autophagy 35 
and investigate molecular mechanisms of action and functional outcomes in relation to this 36 
cellular process.  37 
Methods: Autophagy marker LC3 was evaluated by confocal fluorescence microscopy and 38 
flow cytometry. Drug mechanism of action was investigated by PCR Array with changes in 39 
signaling pathways examined by immunoblot and RT-qPCR. Clearance of adherent-invasive 40 
Escherichia coli (AIEC) and levels of pro-inflammatory cytokine tumour necrosis factor alpha 41 
(TNFα) were evaluated by gentamicin protection assays and RT-qPCR respectively. LC3 was 42 
analysed in peripheral blood mononuclear cells (PBMC) from pediatric patients by flow 43 
cytometry. 44 
Results: Azathioprine induces autophagy via mechanisms involving modulation of 45 
mechanistic target of rapamycin (mTORC1) signaling and stimulation of the unfolded protein 46 
response (UPR) sensor PERK. Induction of autophagy with azathioprine correlated with the 47 
enhanced clearance of AIEC and dampened AIEC-induced increases in TNFα. Azathioprine 48 
induced significant increase in autophagosome bound LC3-II in PBMC populations ex vivo, 49 
supporting in vitro findings. In patients, the CD-associated ATG16L1 T300A single-nucleotide 50 
polymorphism did not attenuate azathioprine induction of autophagy.  51 
 4 
Conclusions: Modulation of autophagy via mTORC1 and the UPR may contribute to the 52 
therapeutic efficacy of azathioprine in IBD.  53 
Keywords:  Azathioprine, autophagy, mTORC1, unfolded protein response, Adherent-invasive 54 
E.coli. 55 
  56 
 5 
Introduction 57 
  58 
The inflammatory bowel diseases (IBD), Crohn’s disease (CD), ulcerative colitis (UC) and IBD-59 
unclassified (IBDU), are characterized by chronic inflammation of the gastrointestinal (GI) 60 
tract and have a prevalence of up to 400 per 100,000 people in the United Kingdom 1. The 61 
pathogenesis of IBD is multifactorial in nature, with genetic predisposition, breakdown of the 62 
intestinal epithelial barrier, and concomitant interaction with environmental triggers in the 63 
lumen contributing to disease2. A dysregulated immune response to intestinal microflora has 64 
been heavily implicated, and examination of the disease-associated microbiome has 65 
identified several potentially causative agents 3. Most notably Escherichia coli (E.coli) strains 66 
with an adherent and invasive phenotype (AIEC) have been consistently isolated by 67 
independent investigators from CD patients with ileal disease 4.  68 
Genome-wide association studies (GWAS) have identified 240 IBD susceptibility loci to date5 69 
and have confirmed association with previously recognized susceptibility genes including 70 
Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2). Amongst genes 71 
identified are several linked to autophagy including autophagy-related protein (ATG)16L1, 72 
Immunity-related GTPase family M protein (IRGM) and leucine rich repeat kinase 2 (LRRK2) 6. 73 
Autophagy is an intracellular homeostatic process that involves the formation and maturation 74 
of double membrane vesicles, known as autophagosomes, which engulf cargo that is 75 
degraded upon fusion with lysosomes 7. Autophagy can be an important survival mechanism 76 
that is induced in response to a myriad of stresses. Autophagy plays an essential role in the 77 
innate and adaptive immune responses and the timely resolution of inflammation 8, and loss 78 
of immune regulation is a key event leading to the chronic inflammation observed in CD 9. 79 
Notably, impaired autophagy responses have been observed in a range of cell types derived 80 
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from CD patients including the specialized intestinal epithelial cells (IECs) Paneth cells and 81 
goblet cells, and leukocytes, such as macrophages and dendritic cells (DC) 10.  82 
Evidence suggests that inducing autophagy may have therapeutic benefit for the treatment 83 
of IBD 9. Mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cell 84 
growth and a potent inhibitor of autophagy 10, therefore inhibition of mTORC1 with 85 
rapamycin or its analogues, sirolimus and everolimus, strongly induces autophagy. In 86 
previously reported case studies sirolimus improved symptoms and intestinal healing in a 87 
patient with severe refractory CD 11 and everolimus controlled symptoms for 18 months in a 88 
patient with refractory UC 12. In a study of refractory pediatric IBD, sirolimus induced clinical 89 
remission in 45% of UC patients and 100% of CD patients 13.  90 
Drugs currently approved for clinical use for IBD, including corticosteroids, 91 
immunomodulators, aminosalicylates (5-ASAs) and biologics, target the immune system to 92 
reduce inflammation and induce remission, however response to treatment often diminishes 93 
over time, with 10–35% of CD patients requiring surgery within a year of diagnosis and up to 94 
61% by 10 years 14. A National Health Service review estimated IBD treatment costs of £720 95 
million ($940m) per year in the United Kingdom alone 1, with roughly a quarter of these costs 96 
directly attributed to drug treatments 15. The Crohn’s and Colitis Foundation has recently 97 
highlighted the need for research into optimizing existing medical therapies 16, with patient 98 
stratification of key importance in this context 13. In order to optimize therapies, a more 99 
comprehensive understanding of drug mechanisms of action is required.  100 
We aimed to evaluate current IBD drugs in the context of autophagy and show that the 101 
immunomodulator azathioprine induces autophagy via mechanisms involving modulation of 102 
 7 
mTORC1 and stimulation of the unfolded protein response (UPR) sensor PERK. Our results 103 
suggest that in addition to well-characterized effects on DNA/RNA synthesis and T-104 
lymphocytes 17,18, modulation of autophagy and the UPR may contribute to the therapeutic 105 
efficacy of azathioprine.  106 
  107 
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Materials and Methods 108 
Cell culture, transfection, plasmids and reagents 109 
HEK293 cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Gibco, 110 
ThermoFisher Scientific, Paisley, UK) supplemented with 10% foetal bovine serum (FBS) 111 
(Invitrogen, ThermoFisher Scientific) and penicillin streptomycin (Gibco). The monocytic THP-112 
1 cell line was grown in RPMI 1640 (Sigma-Aldrich, Irvine, UK), supplemented with 10% FBS, 113 
penicillin streptomycin and 200mM L-glutamine (Gibco). For differentiation to macrophages, 114 
THP-1 cells were incubated in RPMI growth media supplemented with 10ng/ml phorbol 115 
myristate acetate (PMA) (Sigma-Aldrich, Dorset, UK) for 48 hr, then rested for 24 hr in fresh 116 
RPMI growth media prior to experiments.  117 
For transfection of HEK293 cells, a Nucleofector Kit V (Lonza Ltd, Manchester, UK) was used 118 
according to the manufacturer’s instructions. The GFP-LC3 19, GFP-RFP-LC3 20 and x-light EGFP 119 
21 plasmids have been described previously. All reagents used are detailed in supplementary 120 
(Table S1). For nutrient deprivation, cells were incubated with Earle’s Balanced Salt Solution 121 
(EBSS) (Gibco).  122 
Immunoblotting 123 
Cells were lysed in ice-cold extraction buffer (50mM Tris [pH 7.6], 150mM NaCl, 5mM EDTA, 124 
0.5% NP-40, 5mM NaF, 1mM sodium vanadate, 1 × Pierce Protease Inhibitor Cocktail [Thermo 125 
Scientific]) for 30 min followed by centrifugation. Protein lysates were resolved by denaturing 126 
electrophoresis on acrylamide/bisacrylamide gels and electro-transferred to Immobilon-FL 127 
PVDF membrane (Merck Millpore EMD, Watford, UK). Membranes were incubated with 128 
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primary antibodies overnight at 4°C, and after washing, were incubated with a secondary 129 
antibody for 1hr at room temperature (RT). Antibody details are provided in (Table S2). 130 
Proteins were visualized by incubation with an ECL western blotting analysis system (GE 131 
Healthcare) and imaged using a G: BOX system (Syngene, Cambridge, UK). Relative intensity 132 
of bands were measured using Image J software 22 (National Institutes of Health, Bethesda, 133 
MD, USA). 134 
Confocal fluorescence microscopy 135 
Cells were seeded on 21-mm borosilicate glass cover slips, 8 chamber polystyrene vessel 136 
CultureSlides (Falcon, Fisher Scientific, Loughborough, UK) or 35mm imaging dishes (Ibidi, 137 
Thistle Scientific, Uddingston, UK). Images were captured using Carl Zeiss LSM880 confocal 138 
microscope (Jena, Germany) and images were analysed using Image J software 18  (National 139 
Institutes of Health). 140 
For fixed cell imaging: Cells were fixed with 4% paraformaldehyde (PFA) for 15 min, 141 
permeabilized with PBS/0.2% Triton X-100 (Sigma Aldrich) and blocked with PBS containing 142 
10% goat’s serum (Gibco) and 2.5% Human TruStain FcX (BioLegend, San Diego, USA). Primary 143 
antibodies (Table S2) were incubated overnight at 4°C and conjugated secondary antibodies 144 
for 1hr at RT. Where appropriate, cells were counterstained with 4′,6′-diamidino-2-145 
phenylindole (DAPI) or mounted with Vectashield mounting medium for fluorescence with 146 
DAPI (Vector Laboratories, Peterborough, UK).  147 
For live cell imaging: Cells were grown in 35mm imaging dishes (Ibidi) and maintained at 37oC 148 
and 5% CO2 in live-cell imaging chamber attached to Carl Zeiss LSM880 confocal microscope. 149 
Images were captured every 2 minutes at x40 magnification over a 12hr time period. 150 
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For autophagy assays in HEK293 GFP-LC3 stable cells: The basal threshold number of GFP-LC3 151 
puncta per cell was established as 5, and cells exhibiting ≥5 puncta were regarded as having 152 
enhanced autophagy activity.   153 
For tandem fluorescent-tagged GFP-RFP-LC3 assays: Cells were transiently transfected with 154 
the GFP-RFP-LC3 plasmid and following designated treatments, the fluorescent autophagy 155 
markers GFP-RFP-LC3 or RFP-LC3 were observed using a confocal microscope and the number 156 
of (RFP+GFP+) and (RFP+GFP-) puncta per cell determined. 157 
Flow cytometry 158 
Peripheral blood mononuclear cells (PBMC) were seeded in 96-well U-bottom plates and cell 159 
lines were seeded in 12-well plates. After treatments, cells were gently detached using 0.05% 160 
trypsin or Cell Dissociation Solution Non-enzymatic (Sigma Aldrich) at 37°C for 10 min. Cells 161 
were acquired using the BD Biosciences (Oxford, UK) Celesta flow cytometer or the 162 
FACSCalibur (BD) and data analysis performed using BD FACsDiva Software or FlowJo 163 
software. 164 
Autophagy assay: For HEK293 GFP-LC3, cells were collected then washed in 0.05% w/v 165 
saponin (Sigma), diluted in PBS to remove the unbound cytosolic LC3 23, which does not alter 166 
expression of membrane antigens 24, prior to acquisition. For PBMC, cells were collected and 167 
blocked with 2.5% Human TruStain FcX in PBS for 20 min, then incubated with PBMC surface 168 
markers or IgG isotypes diluted in Brilliant Stain Buffer (BD Horizon) for 25 min, both at RT. 169 
Cells were then washed in 0.05% w/v saponin, diluted in PBS to remove the unbound cytosolic 170 
LC3, and fixed with 1% PFA for 20 min at 4oC. Cells were washed again with 10% goat serum 171 
in 0.05% saponin before overnight incubation with primary LC3 antibody or Rb IgG Isotype 172 
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control (Invitrogen) in 1% goat serum in 0.05% saponin at 4oC. Secondary antibody in 1% goat 173 
serum in 0.05% saponin was incubated for 30 min at 4oC prior to washing and acquisition.  174 
Annexin-V/PI assay. Cells were stained using the FITC Annexin V Apoptosis Detection Kit I (BD 175 
Pharmingen) according to manufacturer’s instructions.  176 
RT-qPCR 177 
Cells were scraped into RNAzol RT (Sigma-Aldrich) and total RNA extracted according to 178 
manufacturer’s instructions. Total RNA was quantified using a NanoDrop 2000 179 
Spectrophotometer (Thermo Scientific) and integrity was assessed using an Agilent 2100 180 
Bioanalyzer (Agilent Technologies, Stockport, UK) with RNA Nano Chips and Agilent RNA 6000 181 
Nano Reagents (Agilent Technologies). mRNA was converted to cDNA using nanoScript 2, 182 
Reverse Transcription Premix (PrimerDesign Ltd, Chandler´s Ford, UK) according to 183 
manufacturer’s instructions. For qPCR analysis of gene expression PrecisionPLUS Mastermix 184 
with SYBR green and ROX with inert blue dye (PrimerDesign) was used according to 185 
manufacturer’s instructions with RT-PCR Grade Water (Invitrogen) and the StepOnePlus Real-186 
time PCR System (Applied Biosystems, ThermoFisher). Primers are detailed in supplementary 187 
(Table S3). A geNorm kit (PrimerDesign) was used for the selection of appropriate reference 188 
genes (RPL13A [Ribosomal Protein L13a] and Actin) with the qbase+ software 25. 2-ddCT was 189 
used for relative quantification of gene expression 26. The RT² Profiler PCR Array of Human 190 
Autophagy genes (Qiagen, Crawley, UK) was performed according to manufacturer 191 
instructions. 192 
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Bacterial infection assays 193 
For growth curves: LB was inoculated with E. coli strain CUICD541-10 27 isolated from the 194 
ileum of a patient with CD (a kind gift from Prof Kenny Simpson, Cornell University, USA), from 195 
an overnight culture to an optical density of 0.05 at 600nM. Cultures were treated 196 
appropriately, incubated at 37oC with 200rpm shaking, and optical density was measured at 197 
600nM every 30 min.    198 
For intracellular survival: Cells were infected with CUICD541-10 E. coli at a multiplicity of 199 
infection (MOI) of 10 for 3hr, incubated for 1hr in 100μg/ml gentamicin (Gibco) to kill 200 
extracellular bacteria, then maintained for a further 24hr in 20μg/ml gentamicin, with 201 
addition of appropriate treatments for the final 6hr. For colony forming unit (CFU) 202 
enumeration, cells were lysed for 10 min using 1% Triton X100 in PBS. Lysates were serially 203 
diluted and plated on LB agar plates for overnight incubation at 37°C.  204 
For immunofluorescence: CUICD541-10 E. coli transformed with an x-light mCherry plasmid 205 
were used and 30 min prior to immunostaining cells were incubated with 0.1mM isopropyl β‐206 
D‐1‐thiogalactopyranosid (IPTG) (Sigma) to promote bacterial fluorescence. IPTG and 5µM 207 
Cell Tracker Green BODIPY (Invitrogen) were added for the duration of the live-cell imaging 208 
of infected cells.  209 
Patients 210 
Patient recruitment and sample collection was performed at the Royal Hospital for Sick 211 
Children in Edinburgh, and processing and analysis was performed at Edinburgh Napier 212 
University.  213 
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Inclusion criteria were: (1) aged 6-18 years on date of colonoscopy; (2) already confirmed CD, 214 
UC or IBDU 28 or undergoing first upper and lower GI endoscopy due to gastrointestinal 215 
symptoms suggestive of possible bowel inflammation (e.g. abdominal pain, peri-rectal (PR) 216 
bleeding, weight loss). Non-IBD patients were defined as those with both microscopically and 217 
macroscopically normal colonoscopy. Patients were excluded if they had previously 218 
undergone colonoscopy for anything other than known IBD, were diagnosed with anything 219 
other than IBD following a full investigative cycle, or who could not provide written consent. 220 
Whole blood samples (maximum 15ml), and saliva samples were collected from patients: 20 221 
IBD cases and 9 non-IBD controls (Table S4). PBMC were isolated from whole blood using 222 
Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and cultured in RPMI 223 
growth media. Saliva samples were collected using Oragene DNA kits (DNA Genotek, Ontario, 224 
Canada). 225 
Genotyping  226 
Saliva samples were sent to the Wellcome Trust Clinical Research Facility in Edinburgh for 227 
analysis. Once recruitment was completed, DNA was extracted using Isohelix kit and Taqman 228 
genotyping for each sample was performed for the following SNPs: ATG16L1 T300A 229 
(rs2241880), NOD2 L1007f/s (p.Leu1007fsX1008) (rs2066847), NOD2 R702W (rs2066844) and 230 
NOD2 G908R (rs2066845). 231 
Statistical analysis 232 
 14 
Results are reported as the mean ± SEM assuming normally distributed variables with 233 
statistical analysis conducted by using one-way or two-way ANOVA, or paired t-test as 234 
appropriate, with GraphPad Prism version 7.0 (GraphPad Software, CA, USA). 235 
Ethics 236 
All samples were collected with local institutional and NHS ethical approvals (reference 237 
16/WW/0210).  Eligible patients were approached at least 48hr prior to colonoscopy and 238 
following consent were recruited to the study.  239 
Data availability 240 
The datasets generated during and/or analysed during the current study are available from 241 
the corresponding author on reasonable request. 242 
  243 
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Results 244 
Azathioprine induces autophagosome accumulation 245 
To evaluate the modulation of autophagy by IBD drugs we used HEK293 cells, a well-246 
characterized cell line used in autophagy research 29 that were engineered to stably express 247 
the autophagy marker LC3 fused to green fluorescent protein (GFP-LC3) 30. GFP-LC3 puncta 248 
accumulation was measured by live-cell imaging (Figure 1A). Significant increases in GFP-LC3 249 
puncta number were observed after treatment with the immunomodulator azathioprine 250 
(Figure 1A, panel iv and ix) and the biologic infliximab (Figure 1A, panel v and ix) with an 251 
optimal time-point of 6 hr for both drugs (Figure 1A, panel x and xi). Significant increases in 252 
GFP-LC3 puncta were also observed with EBSS to induce nutrient deprivation, a strong 253 
activator of the autophagy pathway (Figure 1A, panel iii and ix). In contrast, the 254 
immunomodulator methotrexate (Figure 1A, panel vi, ix and xii), the corticosteroid 255 
methylprednisolone (Figure 1A, panel vii, ix and xiii) and the aminosalicylate sulfasalazine 256 
(Figure 1A, panel viii, ix and xiv) had no significant effects on GFP-LC3 puncta accumulation.  257 
Azathioprine activates the autophagy pathway 258 
Autophagosomes can accumulate due to activation or inhibition of the autophagy pathway. 259 
To distinguish between these processes, we first employed flow cytometric analysis. To 260 
facilitate measurement of autophagy activation by flow cytometry, HEK293 GFP-LC3 cells 261 
were washed with the glycoside saponin to permeabilize cell plasma membranes prior to 262 
analysis. Plasma membrane permeabilization releases inactive cytosolic LC3, with only the 263 
active lipidated form of LC3-II, which is tightly associated with autophagosome membranes, 264 
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being retained 23 (Supplementary Figure 1). Additionally, Bafilomycin A1 (BafA1), an inhibitor 265 
of autophagosome-lysosome fusion30, was used to augment LC3-II accumulation. Under these 266 
conditions azathioprine clearly enhanced the accumulation of autophagosome-bound GFP-267 
LC3-II (Figure 2A, panel ii and quantified in iv). In contrast, infliximab had only minor additional 268 
effect on GFP-LC3-II accumulation (Figure 2A, panel iii and iv).  269 
To further validate that azathioprine-mediated activation of the autophagy pathway, we 270 
employed a tandem RFP-GFP-LC3 plasmid 31. This RFP-GFP-LC3 plasmid utilises the pH 271 
difference between the acidic autolysosome (formed by fusion of an autophagosome and 272 
lysosome) and the neutral autophagosome, with the pH sensitivity differences exhibited by 273 
GFP (labile at acidic pH) and RFP (stable at acidic pH). Thus, this plasmid can be used to 274 
monitor progression from the autophagosome (RFP+GFP+) to the autolysosome (RFP+GFP-). 275 
HEK293 cells were transfected with RFP-GFP-LC3 plasmid and treated with BafA1, EBSS or 276 
azathioprine. As expected, all three treatments caused autophagosomes to accumulate 277 
(Figure 2B, panel xvi). Inhibition of autophagosome-lysosome fusion with BafA1 resulted in 278 
the accumulation of  (RFP+GFP+) puncta, which appear as yellow in the merged image (Figure 279 
2B, panel x, xiii and quantified in xvii), while activation of the pathway with EBSS resulted in 280 
an accumulation of (RFP+GFP-) puncta indicating that complete progression through the 281 
pathway was taking place (Figure 2B, panel xi, xiv and xvii). Azathioprine treatment resulted 282 
in an accumulation of (RFP+GFP-) puncta relative to untreated control (Figure 2B, panel xii, xv 283 
and xvii) indicating that azathioprine activates the autophagy pathway. 284 
Azathioprine induces autophagosome accumulation in macrophages 285 
independent of apoptosis 286 
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As with other biological processes, autophagy is cell-type specific and it is therefore essential 287 
to determine how azathioprine modulates the autophagy pathway in cell types of direct 288 
relevance to IBD. For this purpose, macrophages derived from THP-1 cells were treated with 289 
azathioprine and endogenous LC3 puncta accumulation measured by fixed-cell confocal 290 
fluorescence microscopy. In line with our previous results (Figure 1A), azathioprine treatment 291 
significantly increased the number of LC3 puncta in THP-1 derived macrophages (Figure 3A, 292 
panel iv and v). Autophagy and apoptosis are intimately linked 32, therefore it was also 293 
important to determine the effect of azathioprine on apoptosis in these cells. Analysis of 294 
Annexin V/PI staining by flow cytometry revealed that azathioprine had no effect on cell 295 
viability at either 6 hr or 24 hr treatment (Figure 3B, panel ii, iv, and v). Together, these results 296 
demonstrate that azathioprine induces autophagosome accumulation in THP-1 derived 297 
macrophages independent of apoptosis. 298 
Azathioprine stimulates the UPR  299 
To gain insight into azathioprine mechanism of action, we used the Human Autophagy RT² 300 
Profiler PCR Array. Gene expression was compared in THP-1 derived macrophages either left 301 
untreated or treated with azathioprine (Figure S3).  Among the genes significantly up-302 
regulated by azathioprine was the UPR-regulating kinase EIF2AK3 (also known as PERK). As 303 
endoplasmic reticulum (ER)-stress/UPR genes are strongly associated with IBD this was 304 
investigated further 33. A time-course RT-qPCR experiment identified 6 hr as the optimum 305 
time-point for up regulation of PERK, which occurred in a dose-dependent manner (Figure 4, 306 
panel i and ii). The expression of genes downstream from PERK (ATF4, and CHOP; Figure 4, 307 
panel iii and iv), and the ER stress chaperon protein disulphide isomerase (PDI) (Figure 4, panel 308 
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vi) were also up regulated after 6 hr of azathioprine treatment in a dose dependent manner. 309 
In contrast, expression of the ER stress chaperone protein binding immunoglobulin 310 
protein/78-kDa glucose-regulated protein (BiP/Grp78) was not affected by azathioprine 311 
treatment after 6 hr (Figure 4, panel vii) however a minor increase was observed after 24 hr. 312 
These results indicate that azathioprine stimulates the UPR.   313 
Azathioprine modulates mTORC1 signaling 314 
mTORC1 is a major regulatory hub balancing cell growth and protein translation with control 315 
of autophagy 34. When active, mTORC1 is a potent inhibitor of autophagy. Therefore, levels 316 
of phosphorylated ribosomal protein S6 (p-rpS6), a surrogate marker of mTORC1 activity, 317 
were evaluated in THP-1 derived macrophages treated with increasing concentrations of 318 
azathioprine. Azathioprine treatment caused a dramatic decrease in p-rpS6 in a dose 319 
dependent manner (Figure 5A, lanes 3-6 and quantified in ii). These results suggest that 320 
azathioprine treatment inhibits mTORC1 activity. 321 
Azathioprine modulates mTORC1 signaling independent of PERK 322 
PERK has been shown to inhibit mTORC1 in response to ER stress as part of a mechanism to 323 
induce autophagy 34–36. To test whether modulation of mTORC1 observed in response to 324 
azathioprine is dependent on PERK, THP-1 derived macrophages were treated in the absence 325 
or presence of a pharmacologic inhibitor of PERK. Azathioprine again caused a decrease in p-326 
rpS6, and the PERK inhibitor did not significantly alter this effect (Figure 5B, panel i, compare 327 
lanes 3 and 8, and quantified in ii). To confirm PERK inhibitor activity, phosphorylation of 328 
eIF2a, a well-characterized substrate of PERK, was assessed (Figure 5B, lanes 6-10 and 329 
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quantified in iii). These results suggest that modulation of mTORC1 signaling by azathioprine 330 
occurs independent of PERK. 331 
Azathioprine-induced autophagy is modulated by PERK 332 
To determine whether PERK is required for azathioprine-induced autophagy, THP-1 derived 333 
macrophages were treated with azathioprine or EBSS in the absence or presence of PERK 334 
inhibitor. In the presence of PERK inhibitor, azathioprine-induced autophagy was specifically 335 
attenuated (Figure 5C, compare panel ii and v, and quantified in vii) compared to EBSS-336 
induced autophagy (Figure 5C, compare panel iii and vi, and quantified in vii). These results 337 
indicate that PERK is an important factor regulating azathioprine-induced autophagy.  338 
Azathioprine enhances clearance of intracellular AIEC 339 
Evidence suggests that AIEC play a putative role in CD 37. Therefore, we evaluated the survival 340 
of the CD mucosa-associated AIEC strain CUICD541-10 27 in THP-1 derived macrophages. 341 
Initially, it was determined that azathioprine had no direct effect on bacterial growth (Figure 342 
S3). Azathioprine treatment did however cause a significant decrease in bacterial CFU in AIEC 343 
infected cells (Figure 6A). Furthermore, immunofluorescence analysis showed a decrease in 344 
the percentage of cells infected with bacteria (Figure 6B and C, compare panels iii and iv and 345 
quantified in v), which correlated with an increased accumulation of LC3 puncta (Figure 6C 346 
panel v) indicating that autophagy was being induced.  347 
Infection of cells with AIEC elicits a strong inflammatory response; therefore, RT-qPCR was 348 
used to assess expression of the pro-inflammatory cytokine TNFα in THP-1 derived 349 
macrophages infected with AIEC. Expression was significantly up regulated by AIEC infection 350 
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and this was reduced when cells were treated with azathioprine (Figure 6D, panel i). 351 
Azathioprine also reduced the expression of TNFα in cells treated with bacterial 352 
lipopolysaccharide (LPS) (Figure 6D, panel ii) suggesting that azathioprine may affect TNFα 353 
expression independent of decreased intracellular bacteria. These results demonstrate that 354 
azathioprine enhances the clearance of intracellular AIEC and dampens the elevated cytokine 355 
levels observed in response to infection. 356 
Azathioprine activates autophagy in PBMC and monocytes from 357 
pediatric patients 358 
Non-IBD, CD and UC patients were genotyped for the CD-associated NOD2 (R702W, G908R, 359 
L1007fs) and ATG16L1 T300A SNPs (Table 1). PBMC from the patient groups were then 360 
assessed for autophagy activity by flow cytometry. No significant differences in basal 361 
autophagy activity were observed, and azathioprine treatment resulted in an accumulation 362 
of autophagosome-bound LC3-II in PBMC from all patient groups (Figure 7A, panel i).  Analysis 363 
of basal autophagy activity in untreated monocytes revealed no difference across the patient 364 
groups and azathioprine treatment again enhanced the accumulation of autophagosome-365 
bound LC3-II (Figure 7A, panel ii). Similar results were observed in monocyte subsets, in 366 
addition to T cells, B cells and NK cells (Figure S4). Interestingly, activation of autophagy by 367 
azathioprine was not attenuated in PBMC heterozygous or homozygous for the ATG16L1 368 
T300A SNP (Figure 7A, panel iii). The low frequency of NOD2 SNPs present in the cohort 369 
precluded analysis of effect on azathioprine-induced autophagy. Taken together, these 370 
results demonstrate that azathioprine activates autophagy in primary cells ex vivo, supporting 371 
our in vitro findings. 372 
373 
 21 
Discussion  374 
 375 
The strong association of CD with autophagy genes has led to a substantial amount research 376 
demonstrating several key functions for autophagy including regulation of the innate and 377 
adaptive immune responses, regulation of the intestinal microbiome and resolution of ER-378 
stress 9,10. Impaired autophagy responses have been observed in a range of cell types derived 379 
from CD patients 10, and there is mounting evidence that inducing autophagy can have 380 
therapeutic benefits for the treatment of IBD in both pediatric and adult patients, with several 381 
recent studies investigating the utility of mTORC1 inhibitors 12,13,38. Despite these advances in 382 
understanding, there is still little known about how drugs currently approved for clinical use 383 
in IBD affect autophagy function.  384 
To evaluate current IBD drugs in the context of autophagy we initially screened for the 385 
accumulation of autophagosomes using live cell imaging and identified azathioprine and 386 
infliximab as potential modulators of autophagy. However, further investigation using flow 387 
cytometry to measure the active, lipidated form of LC3-II revealed that only azathioprine 388 
activated the autophagy pathway. Furthermore, results with the GFP-RFP-LC3 plasmid 389 
demonstrate that autophagic flux is enhanced in the presence of azathioprine.  390 
Thiopurines are a class of immunosuppressant drugs that includes azathioprine, 391 
mercaptopurine (6-MP), and thioguanine (6-TG). It is well-established that thiopurines can 392 
inhibit DNA/RNA synthesis and deactivate pro-inflammatory T-lymphocytes 17,18, however, 393 
their mechanism of action is not fully understood. Interestingly, several previous studies have 394 
also found that thiopurines can activate autophagy primarily via DNA mismatched repair 395 
processes in response to DNA damage 9. To date, only one study has shown autophagy 396 
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induction mediated by azathioprine, in colorectal carcinoma cells 39. The authors suggest that 397 
increased autophagy associated with thiopurine exposure is a survival mechanism to 398 
compensate for a primary effect on apoptosis and mitochondrial damage. Mechanistically, 399 
we show an alternative autophagy-associated process whereby azathioprine increased the 400 
expression of several UPR genes including PERK, ATF4 and CHOP as well as expression of the 401 
ER-stress chaperone protein PDI. Importantly, we demonstrate that azathioprine induces 402 
autophagy independent of apoptosis. 403 
The ER-stress/UPR pathways play an essential role in the maintenance of intestinal 404 
homeostasis and genetic studies have identified several ER-stress/UPR genes associated with 405 
IBD 33. Significantly, ER-stress levels are increased in ileal and colonic biopsies from CD 406 
patients 40–43. The UPR acts to maintain ER-homeostasis, and cells that naturally secrete large 407 
amounts of protein, such as Paneth cells strongly linked to ileal CD are more susceptible to 408 
ER-stress and therefore rely heavily on the UPR 44 .  409 
The UPR and autophagy are intimately linked processes 45, to relieve ER-stress the UPR can 410 
induce autophagy to degrade misfolded proteins and protein aggregates 46–50. Importantly, 411 
the major risk factors for CD, NOD2 and ATG16L1, functionally intersect with ER-stress and 412 
the UPR 51 52, and ER stress is a significant risk when autophagy or the UPR is not functional. 413 
The convergence between autophagy and UPR pathways provides new opportunity for the 414 
treatment of IBD and the modulation of the UPR in combination with autophagy is a promising 415 
therapeutic strategy. In support of this idea, several recent studies have demonstrated 416 
beneficial effects of enhancing UPR function for intestinal homeostasis 53–55.  417 
We also show that azathioprine modulates mTORC1 signaling. A growing body of work 418 
suggests that the UPR is regulated by diverse stimuli independently of ER-stress 56 and 419 
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stressors such as nutrient deprivation and hypoxia have been shown to activate UPR signaling 420 
and inhibit mTORC1 57. UPR activation can occur both upstream and downstream of mTORC1 421 
57, and mTORC1 inhibitors, including rapamycin, are reported to induce PERK and eIF2α  422 
activation 58. Our finding that PERK inhibition did not affect the mTORC1 response to 423 
azathioprine suggests that mTORC1 may be acting upstream or in parallel to PERK. 424 
Significantly, azathioprine-induced autophagy was reduced in the presence of PERK inhibitor, 425 
supporting others findings that PERK regulates LC3B and ATG5 expression 59. Our results 426 
suggest that azathioprine is acting through a pathway that involves both mTORC1 and PERK, 427 
and may have synergistic outcomes; mTORC1 inhibition and PERK-eIF2α stimulation may 428 
work together to inhibit global protein translation, while mTORC1 inhibition together with 429 
increased expression of autophagy genes by PERK 60,61, may result in a general increase in 430 
autophagic activity.  431 
AIEC are prevalent in ileal mucosa of CD patients 62 and are able to survive and replicate within 432 
macrophages, resulting in sustained inflammatory responses 63 and granuloma formation 64. 433 
Using a CD mucosa-associated strain of AIEC we show that azathioprine enhances the 434 
clearance of intracellular bacteria from THP-1 derived macrophages independent of direct 435 
effects on bacterial growth. Importantly, AIEC clearance correlated with increased autophagy 436 
and reduced pro-inflammatory cytokine gene expression.  These combined effects of 437 
azathioprine may make it a preferred therapeutic option for subsets of patients with 438 
confirmed AIEC infection.  439 
Finally, we carried out an observational study of a clinical cohort of children. PBMC from non-440 
IBD patients or patients with the diagnosis of IBD were analysed to determine basal 441 
autophagy levels and response to azathioprine treatment ex vivo. Our flow cytometry results 442 
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revealed that basal autophagy levels and azathioprine-induced autophagy were similar in all 443 
patient groups.  Similar results were also observed when we analysed subsets of monocytes, 444 
T cells, B cells and NK cells.  Importantly, it has been shown that autophagy is required for the 445 
differentiation of monocytes to macrophages 65, and for the induction of macrophages which 446 
display immunosuppressive and wound healing properties 66. Our results suggest that 447 
enhancing autophagy with azathioprine may promote the induction of macrophages with an 448 
anti-inflammatory phenotype irrespective of diagnosis.   449 
Greater understanding of the genetic factors that underlie CD pathogenesis are leading to 450 
improvements in treatment, and genotyping for key SNPs in genes involved in both the 451 
autophagy and ER-stress/UPR pathways may help to predict patient response to drugs. For 452 
example, recent studies have identified an association between ATG16L1 T300A SNP and an 453 
enhanced therapeutic effect of thiopurines 67 and anti-TNF-α therapy 68. Interestingly, the 454 
immunoregulatory effects of these drugs were associated with autophagy stimulation 66,67,69. 455 
For instance, cytoskeletal defects that reduced mobility in autophagy-deficient DC harbouring 456 
the ATG16L1 T300A SNP were reversed by thiopurine inhibition of Ras-related C3 botulinum 457 
toxin substrate 1 (RAC1) 67. Significantly, analysis of ATG16L1 genotype in our pediatric cohort 458 
revealed that the autophagy response to azathioprine was not attenuated in PBMC from 459 
patients carrying the CD-associated T300A SNP. The ATG16L1 T300A risk variant confers 460 
greater risk for CD in pediatric patients than in adult patients 70,71 , therefore it will be 461 
interesting to compare results in PBMC from an adult cohort. Collectively, our studies suggest 462 
that patients harbouring the ATG16L1 risk variant may benefit from thiopurines via 463 
mechanisms involving RAC1 inhibition and the induction of autophagy. 464 
Conclusion  465 
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Breakdown of the ER-stress/UPR and autophagy pathways has been strongly linked to 466 
pathogenesis of IBD. Together, our results suggest that stimulation of autophagy and the UPR 467 
may contribute to the therapeutic efficacy of azathioprine. Additional studies are now 468 
required to further elucidate how thiopurines modulate these converging pathways; results 469 
of these studies may pave the way for development of the next generation of drugs aimed at 470 
modulation of the UPR in combination with autophagy. 471 
Autophagy is a cell type specific process, therefore it is essential to assess whether 472 
thiopurines modulate autophagy and the UPR in other cell types of direct relevance to IBD, 473 
such as Paneth cells strongly linked to ileal CD. Specifically, studies conducted in cells from 474 
patients with known CD-associated mutations in the genes regulating the ER-stress/UPR and 475 
autophagy pathways will help to identify patients that are most likely to respond. 476 
 477 
 478 
 479 
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Abbreviations  675 
5-ASA  Aminosalicylates 676 
AIEC  Adherent Invasive E. coli   677 
ATF6  Activating transcription factor 6 678 
ATG16L1 Autophagy-related protein 16-1 679 
BafA1  Bafilomycin A1 680 
BiP/Grp78 Binding immunoglobulin protein/78-kDa glucose-regulated protein 681 
CD  Crohn’s disease 682 
CFU  Colony forming units 683 
DAPI  4′,6′-diamidino-2-phenylindole 684 
DC  Dendritic cell 685 
DMEM  Dulbecco’s modified Eagle medium 686 
EBSS  Earle’s Balanced Salt Solution 687 
E. coli   Escherichia coli 688 
EIF2a  Eukaryotic translation initiation factor 2A 689 
ER  Endoplasmic Reticulum 690 
FBS  Foetal bovine serum  691 
GI  Gastrointestinal tract  692 
GWAS  Genome-wide association studies 693 
IBD  Inflammatory Bowel Disease 694 
IBDU  IBD-unclassified  695 
IPTG  isopropyl β‐D‐1‐thiogalactopyranosid 696 
IRE1α  Inositol-requiring enzyme 1α 697 
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IRGM  Immunity-related GTPase family M protein 698 
LC3  MAP1LC3B 699 
mTORC1 Mechanistic target of rapamycin  700 
MOI  Multiplicity of infection  701 
NOD2  Nucleotide-binding oligomerisation domain-containing protein 2 702 
PBMC  Peripheral blood mononuclear cells 703 
PDI  Protein disulphide isomerase 704 
PERK   Protein kinase R (PKR)-like endoplasmic reticulum kinase 705 
PFA  Paraformaldehyde 706 
PMA  Phorbol myristate acetate  707 
RAC1  Ras-related C3 botulinum toxin substrate 1 708 
p-rpS6  Phosphorylated ribosomal protein S6 709 
TNF-α  Tumour necrosis factor alpha 710 
UC  Ulcerative colitis  711 
UPR  Unfolded protein response 712 
XBP1  x-box-binding protein 1 713 
 714 
Table 1. Pediatric patient genotype 715 
CD Crohn’s disease, UC Ulcerative colitis, IBDU IBD unclassified. ATG16L1 T300A genotype: 716 
rs2241880. *NOD2 genotype SNPs: L1007fs (rs2241880), G908R (rs2066845) and R702W 717 
(rs2066844). 718 
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 Non-IBD CD UC IBDU 
Cohort (n=29) 9 12 7 1 
Genotype ATG16L1 T300A (n=26) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
1 
3 
3 
 
2 
6 
4 
 
1 
3 
3 
 
N/A 
N/A 
N/A 
Genotype NOD2 L1007fs (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
8 
0 
0 
 
12 
0 
0 
 
7 
0 
0 
 
N/A 
N/A 
N/A 
Genotype NOD2 G908R (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
8 
0 
0 
 
11 
0 
1 
 
7 
0 
0 
 
N/A 
N/A 
N/A 
Genotype NOD2 R702W  (n=27) 
Wildtype 
Heterozygous risk 
Homozygous risk 
 
7 
0 
1 
 
11 
1 
0 
 
6 
0 
1 
 
N/A 
N/A 
N/A 
 719 
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Figure Legends  720 
Figure 1: Modulation of autophagy by current IBD drugs  721 
HEK293 GFP-LC3 cells were untreated (i) or treated with DMSO (ii), EBSS (iii), 120μM 722 
Azathioprine (iv and x), 100μg/ml Infliximab (v and xi), 120μM Methotrexate (vi and xii), 723 
100μM methylprednisolone (vii and xiii) or 150μM sulfasalazine (viii and xiv) and assessed by 724 
live-cell confocal microscopy up to 12hr. 50 cells counted from 3 fields of view and percentage 725 
cells with >5 GFP-LC3 puncta quantified (+/- SEM) for all time-points (x-xiv) with 6hr time-726 
point highlighted **p <0.01; ****p < 0.0001 (ix). 727 
Figure 2: Azathioprine activates the autophagy pathway 728 
A) HEK293 GFP-LC3 cells were treated for 6hr with 160nM BafA1 only or BafA1 plus EBSS (i), 729 
BafA1 plus 120μM azathioprine (ii) or BafA1 plus 100μg/ml Infliximab (iii). Geometric mean 730 
of GFP-LC3-II intensity was assessed by flow cytometry. Fold-change in GFP-LC3-II geometric 731 
mean from BafA1 only was quantified (+/-SEM) (iv).  732 
B) HEK293 cells were transfected with GFP-RFP-LC3 plasmid and left untreated (i, v, ix) or 733 
treated with 160nM BafA1 (ii, vi, x), EBSS (iii, vii, xi), or 120µM azathioprine (iv, viii, xii) for 6hr, 734 
and imaged by confocal microscopy. Percentage of transfected cells exhibiting >10 LC3 puncta 735 
was quantified (+/-SEM) (n=5) (xiii) *p <0.05. Number of (RFP+GFP+) and (RFP+GFP-) LC3 736 
puncta were quantified (+/-SEM) (n=5) (xiv) **p <0.01, ***p <0.001. 737 
Figure 3: Azathioprine induces autophagosome accumulation independent of apoptosis 738 
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 A) THP-1-derived macrophages were untreated (i), or treated with DMSO (ii), EBSS (iii), or 739 
120µM azathioprine (iv) for 6hr. Cells were then immunostained for endogenous LC3 and 740 
imaged by confocal microscopy. 30 cells were counted from 3 fields of view and percentage 741 
cells with >5 GFP-LC3 puncta quantified (+/- SEM) *p <0.05; **p < 0.01 (v).  742 
B) THP-1-derived macrophages were left untreated (i, v) or treated with DMSO (ii, vi), 120μM 743 
azathioprine (iii, vii) or 30µM camptothecin (iv, viii) for 6hr (i-iv) and 24hr (v-vii). Cells were 744 
stained with Annexin-V/PI and analysed by flow cytometry. Mean percentage population in 745 
each quadrant was quantified (+/- SEM) **p value <0.01, ***p value <0.001, ****p value 746 
<0.0001 (ix) compared to untreated for corresponding time-point and quadrant. 747 
Figure 4: Azathioprine stimulates the UPR 748 
THP-1-derived macrophages were left untreated, or treated with DMSO, 60µM or 120µM 749 
azathioprine, or EBSS for 2, 4, 6, 16 and 24hr. Expression of PERK was determined by RT-qPCR 750 
and is displayed in Log10 scale (i). 6hr time-point, including treatment with 0.5μg/ml Brefeldin 751 
A quantification (+/- SEM) is shown for PERK (ii), ATF4 (iii), CHOP (iv), PDI (vi) and BiP (vii). 752 
Using 2-ddct : *p <0.05, **p <0.01, ****p <0.0001.  753 
Figure 5: Azathioprine modulates autophagy via mechanisms involving mTORC1 and PERK.  754 
A) THP-1-derived macrophages were left untreated or treated with DMSO, azathioprine (60-755 
120μM), EBSS or the mTORC1 inhibitor rapamycin (100nM) for 6hr. Protein lysates were 756 
immunoblotted for rpS6, phosphorylated rpS6 (p-rpS6 (S235/236)) and actin (i). rpS6/p-rpS6 757 
density normalized to actin was quantified as a percentage of untreated (ii). Representative 758 
blot from n=3. 759 
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B) THP-1-derived macrophages were left untreated, or treated with DMSO, 120µM 760 
azathioprine, EBSS, or 0.5μg/ml Brefeldin A for 6hr in the absence or presence of PERK 761 
inhibitor. Protein lysates were immunoblotted for rpS6, phosphorylated rpS6 (p-rpS6 762 
(S235/236)), phosphorylated eIF2α (p-eIF2α (S51) and tubulin (i). rpS6/p-rpS6 density (ii) and 763 
p-eIF2α density (iii) normalized to tubulin was quantified. Representative blot from n=3. 764 
C) THP-1-derived macrophages were left untreated, or treated with 120µM azathioprine, or 765 
EBSS for 6 hr in the absence (i-iii) and presence (iv-vi) of PERK inhibitor and immunostained 766 
for LC3. 100 cells were counted per treatment and percentage cells with >5 GFP-LC3 puncta 767 
quantified (+/- SEM) *p <0.05 (vii). 768 
Figure 6: Azathioprine enhances clearance of intracellular AIEC and dampens the 769 
inflammatory response.  770 
A) THP-1-derived macrophages were infected with AIEC and gentamicin protection assay 771 
performed in the absence or presence of DMSO or 120µM azathioprine. CFU/ml of cell lysates 772 
were enumerated, and fold-change mean CFU/ml from untreated was calculated (+/- SEM), 773 
**p <0.01.  774 
B and C) THP-1-derived macrophages were infected with AIEC-mCherry and gentamicin 775 
protection assay performed in the absence or presence of DMSO or 120µM azathioprine. 776 
Fluorescent AIEC were enumerated and percentage cells with intracellular bacteria quantified 777 
(+/- SEM), *p <0.05, **p <0.01, ***p <0.001. 778 
D) THP-1-derived macrophages were infected with AIEC (i) or treated with 200ng/ml LPS (ii) 779 
and left untreated or treated with DMSO or 120µM azathioprine for 6hr. Expression of TNF-α 780 
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was normalized to untreated and mean fold-change expression quantified from n=3 (+/- SEM) 781 
(i-ii). Using 2-ddct : *p <0.05. 782 
Figure 7: Azathioprine activates autophagy in PBMC and monocytes from pediatric patients.  783 
PBMC isolated from non-IBD control and IBD patients were left untreated or treated with 784 
120μM azathioprine for 6hr. PBMC were stained with surface markers for classification into 785 
populations and for endogenous LC3-II. Geometric mean of LC3-II intensity was quantified by 786 
flow cytometry and mean of LC3-II geometric mean (+/-SEM) is shown for total PBMC (I, iii) 787 
and total monocytes (ii) for each non-IBD and IBD patient group (i-ii) and each ATG16L1 788 
genotype (iii). One-way ANOVA with Tukey’s multiple comparison was used to compare LC3-789 
II geometric mean between patient groups in untreated cells. Within each patient group 790 
paired, two tailed t test was used to compare LC3-II geometric mean of untreated and 791 
azathioprine-treated cells.  *p < 0.05, **p <0.01. 792 
Table S1: Concentration and manufacturer details of reagents used for cell treatments. 793 
Working concentrations were diluted in appropriate growth media.  794 
Table S2: Antibody details  795 
WB western blot, IF immunofluorescent staining, F flow cytometry, IHC 796 
immunohistochemistry. All primary and secondary antibodies were prepared in 1% FBS or 797 
goat serum. 798 
Table S3: qPCR Primer Details 799 
FW forward and RV reverse primer sequences. 800 
Table S4: Pediatric patient demographics  801 
 40 
CD Crohn’s disease, UC Ulcerative colitis, IBDU IBD unclassified. SD Standard deviation. *Non-802 
IBD diagnosis included normal (4 patients), mild constipation (1 patient), Irritable Bowel 803 
Syndrome (IBS) (3 patients) and threadworms (1 patient). aParis Classification for CD: L1 ileal, 804 
L2 colonic, L3 ileocolonic, L4a upper disease proximal to ligament of Treitz; B1 non-stricturing 805 
and non-penetrating, B2 stricturing, B3 penetrating, p perianal disease modifier 72. bParis 806 
Classification for UC: E1 ulcerative proctitis, E2 left-sided UC (distal to splenic flexure), E3 807 
extensive (hepatic flexure distally), E4 pancolitis (proximal to hepatic flexure); S0 never 808 
severe, S1 ever severe as defined by Pediatric Ulcerative Colitis Activity Index (PUCAI) 72. 5-809 
ASA 5-aminosalisylates. 810 
Figure S1: GFP-LC3 Flow Cytometry in HEK293 GFP-LC3 cells.  811 
Schematic diagram showing cell permeabilization with 0.05% saponin to remove cytosolic 812 
GFP-LC3 to allow flow cytometery analysis 23 (i). HEK293 GFP-LC3 cells were either untreated 813 
or treated with 160nM bafilomycin for 6 hours. Cells were washed without (ii) or with (iii) cell 814 
permeabilization with 0.05% saponin to remove cytosolic GFP-LC3 before fixation. Geometric 815 
mean of GFP-LC3 fluorescent intensity of cells was quantified by flow cytometry and analysed 816 
using FlowJo software (ii-iii). 817 
Figure S2: Differentially Expressed Genes from RT2 Profiler™ PCR Array for Human 818 
Autophagy Genes when treated with Azathioprine  819 
THP-1-derived macrophages were untreated or treated with 120µM azathioprine for 6 hours. 820 
mRNA was extracted and converted to cDNA for RT-qPCR analysis using the RT² Profiler™ PCR 821 
Array for Human Autophagy genes according to manufacturer instructions. The calibrating 822 
sample was untreated cells and relative expression for azathioprine treatment is displayed as 823 
fold-change, with upregulated genes calculated as 2-ddCT and downregulated genes as 2ddCT. 824 
Differentially expressed genes are shown, with 1.5-fold change in expression considered as 825 
the threshold for differential expression.  826 
Figure S3: Effect of azathioprine on growth of AIEC, clearance of intracellular AIEC and pro-827 
inflammatory cytokine responses  828 
 41 
LB broth was inoculated from an overnight culture of AIEC to an optical density of 0.05 at 829 
600nm. The cultures were untreated, or treated with DMSO, or 120μM of azathioprine and 830 
incubated at 37oC with shaking at 200RPM. Optical density at 600nm was measured every 0.5 831 
hours and plotted in logarithmic scale to show growth phases.    832 
Figure S4: Azathioprine activates autophagy in monocyte subsets, T cells, B cells and NK 833 
cells from pediatric patients.  834 
PBMC isolated from non-IBD control and IBD patients were left untreated or treated with 835 
120μM azathioprine for 6h. PBMC were stained with surface markers for classification into 836 
populations and for endogenous LC3-II. Geometric mean of LC3-II intensity was quantified by 837 
flow cytometry and mean of LC3-II geometric mean (+/-SEM) is shown for classical monocytes 838 
(i), intermediate monocytes (ii), non-classical monocytes (iii), T cells (iv), B cells (v) and NK 839 
cells (vi) for each non-IBD and IBD patient group. One-way ANOVA with Tukey’s multiple 840 
comparison was used to compare LC3-II geometric mean between patient groups in 841 
untreated cells. Within each patient group paired, two tailed t test was used to compare LC3-842 
II geometric mean of untreated and azathioprine-treated cells.  *p < 0.05, **p <0.01. 843 
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